



Declaration of Conflict of Interest or Relationship

Speaker Name: Richard G. Spencer

I have no conflicts of interest to disclose with regard to the subject matter of this presentation.

*T*oronto!

Unmet Needs for MR in the Unsolved Problem of Tissue Engineering:

Not just one problem, not just one solution

Richard G. Spencer

Magnetic Resonance Imaging and Spectroscopy Section
National Institute on Aging, NIH
Baltimore, MD

Definition of Tissue Engineering:

"...an interdisciplinary field that applies the principles of engineering and life sciences towards the development of biological substitutes that restore, maintain, or improve tissue function."

Langer and Vacanti, 1993

Tissue Engineering

Includes:

- Implanted cellular constructs designed in the lab
 - off-the-shelf cartilage, pancreas, liver, ...*
- Implanted cells which will develop function in vivo
 - stem cells for MI or stroke repair*
 - cartilage matrix from implanted cells*
- Implanted acellular scaffolds
 - bioactive bone graft scaffold*

Excludes:

- Organ transplants
- Artificial mechanical organs
- Metal joints
- Hemodialysis, external blood oxygenators,...

Motivation for TE

Limitations of non-biologic repair:

- Duration < longevity of patient
(metal implants)
- Highly invasive
(hemodialysis)
- Typically, no growth or adaptation
(c.f. advantage of demand pacemakers)

Funding Opportunities

NIH: regenerative medicine funding 2008--
US\$575 M (approx. 2% of NIH budget)

DoD: Armed Forces Institute of Regenerative
Medicine (AFIRM), April, 2008:
US\$265 M over 5 years

Other: NIST, NSF, Arthritis Foundation,
Musculoskeletal Transplant Foundation...

The product list is limited but active

- *Medtronic: INFUSE bone grafts*




- *RESTORE small intestine submucosa (duPont)*



- *Apligraf skin patch (Organogenesis)*



- *Cord blood stem cell banking*



**TABLE 3. COMMERCIAL PRODUCTS (ROUNDED TOTALS;
\$ [MILLIONS])**

<i>Commercial products</i>	<i>2007 sales</i>	<i>Cumulative patients</i>
Bioactive bone grafts	\$700	170,000
Regenerative biomaterials (SIS)	\$240	750,000
Cord stem cells	\$270	*
LSE and cartilage	\$90	250,000

LSE: Living skin equivalent.

*Cord stem cell donors are not classified as patients.

Private sector activity, 2007 (worldwide)

of firms or business units > 50

of employees > 3000

Annual sales > US\$1.3 billion

of patients treated > 1M

products in preclinical stages > 50

What Can MRI and MRS Contribute?


Non-invasive ↻ Monitoring after Implantation

- Positional stability
- Integration with surroundings
- Metabolic activity
- Need for and response to ongoing intervention


"Structural imaging" may be less important than other capabilities of MR, such as more specific microstructural and molecular analyses, and metabolic analysis

Examples of Current MR/TE Studies

TE Cartilage Development in Hollow-fiber Bioreactor




Bovine neocartilage developing from chondrocytes




MT of TE Cartilage


1 week




2 weeks




3 weeks




4 weeks




Blue: $MT < 0.4$ Red: $MT > 0.8$



Neocartilate in Bioreactor




Effect of ibuprofen on developing cartilage




Effect of chondroitinase on developing cartilage

MR Image



Matrix containing iron-labeled cells




Prussian blue stained section

Non-labeled matrix

Day 14

Non MRI: Model Based Estimates

(Sengers B. G. et al. JBME 2005)



Computed spatial glucose concentration

Fick's law

$$\frac{\partial n^f c^B}{\partial t} - D \frac{\partial^2 c^B}{\partial x^2} = q^B,$$


Michaelis-Menten

$$q^{\text{glc}} = - \frac{V^{\text{glc}} c^{\text{glc}}}{K_m^{\text{glc}} + c^{\text{glc}}} \rho^{\text{cell}},$$

Metabolic Mapping in TE cartilage


¹H Localized Spectroscopy in Collagen I Constructs

Time course of glucose diffusion into ROI_1







Direct measurement of spatial glucose concentration

Reference geometry of collagen I gel



Courtesy David Reiter

Cartilage/Hydrogel Studies




Courtesy S. Ramaswamy, Bioengineering, Univ of Pittsburgh

Assessment of Cartilage formed in Self-Aggregating Suspension Culture

Characteristics of Culture Model

- Grows in suspension at high density ($1-2 \times 10^7$ cells/ml)
- Forms a mass quickly (1 \rightarrow 10 weeks mass >6 fold)
- Maintains cartilage phenotype (cartilage specific ECM, no Coll I)





Bovine patellar cartilage

Engineered cartilage

Previous studies:


Direct correlation of $T_{1\rho}$ MR measurements with FCD and PG in cartilage

MR-based methods offer advantages of providing noninvasive, nondestructive, and quantitative surrogate measures of material properties.




MRI Following Matrix-assisted Autologous Chondrocyte Transplantation

T₂-weighted fast spin echo images reveal longitudinal changes in repair zone containing implanted chondrocytes




4 Weeks Post-Surgery:

Fluid-like contrast in repair zone



24 Weeks Post-Surgery:


Heterogeneous contrast



52 Weeks Post-Surgery:

*Repair zone isointense
with native cartilage*

Ostogenesis in a Tissue Engineered Construct



← T₁ weighted image of osteochondral plug

← T₁ and T₂ values for developing TE bone

Conclusion: T₂ is an effective marker for ossification

11.7 T SE; TE/TR=1000/30


Courtesy Richard Magin, UIC

Non-invasive MRI of tissue-engineered bladder construct


Major challenge to successful regeneration: creating immediate angiogenesis

Role for imaging: non-invasive quantitative assessment of angiogenesis

Exposed bladder



Angiogenesis at different VEGF levels
CD31-immunostaining



★ VEGF → ★ microvessel density



Courtesy of Hai-Ling Margaret Cheng, PhD
The Hospital for Sick Children and University of Toronto

Tissue-engineered bladder construct



Gadomer (blood pool cx agent): correlation with microvessel density (MVD) through either fractional plasma volume (v_p) or area under uptake curve (AUC);
→ superior to Gd-DTPA

Gd-DTPA (extracellular cx agent): correlation with MVD is best obtained with AUC

SIGNIFICANCE: MRI measurement of absolute blood volume is feasible in therapeutic angiogenesis paradigms




MR Monitors Viable Cell Number, Bioenergetics and Oxygen Distribution for Mouse Insulinoma β TC Cells in Tissue-Engineered Pancreas




^{31}P 1D CSI yields bioenergetic data with both spatial and temporal resolution.

T_1 of ^{19}F PFTBA shows changes in dissolved oxygen content during hypoxic intervention.



Stem Cell Therapeutics—Cell Persistence



Loss of cells
from
noninfarcted
tissue

Hypointense regions showing sites of
mesenchymal stem cell injection

Tissue properties can often be evaluated
by highly *sensitive*
but *invasive* techniques

- *Gene expression analysis* for genotype and tissue quality
- *Electron microscopy* for microstructure
- *Histology* for exquisite structural detail
- *Immunohistochemistry* for protein expression
- *Optical spectroscopy* for more specific matrix components
- *Microelectrodes / biochemical analysis* for metabolic analysis
- *Mechanical testing* for functional support properties

Unmet Needs

Replacement of gold-standard techniques with non-invasive versions

- Molecule-specific MR:
example: molecular imaging for collagen I vs collagen II
- Mechanical measurements:
example: bone/cartilage elastography; strain measurements
- Sequences and analyses more specific to tissue components
example: water compartment analysis; multiparametric approaches
- Functional analysis (esp. metabolism)
example: localized spectroscopy for cell number and viability
- Histologic-like resolution
example: microscopy

Opportunities Abound!

Caveat:

Capital value of publicly traded TE companies:

2007: \$4.7 billion US



2000: \$2.5 billion US

2003: \$300 million US

Conclusions

- Tissue engineering is currently in a growth phase
- Fundable through several sources
- There is a substantial market presence
(contrast gene therapy)
- MR can actually contribute to further progress
- *Come to the educational session in Hawaii!*

